+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Urokinase Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5820317

According to the American Society of Hematology, Urokinase is used to treat deep vein thrombosis, pulmonary embolism, and peripheral arterial occlusion

The Global Urokinase Market is estimated to be USD 2.62 Bn in 2023 and is expected to reach USD 3.28 Bn by 2028 growing at a CAGR of 4.66%.

Urokinase is an enzyme that is used to break down blood clots in the body, particularly in cases of deep vein thrombosis, pulmonary embolism, and myocardial infarction. The global urokinase market is a growing segment of the pharmaceutical industry, driven by the rising prevalence of pulmonary embolism globally, the usage of urokinase in the treatment of cardiovascular disease, and growing instances of intracerebral hemorrhage.

The rising prevalence of pulmonary embolism (PE) is one of the key drivers of the urokinase market. Urokinase is a type of thrombolytic agent that is used to dissolve blood clots, including those that cause PE. It is an enzyme that is produced naturally by the human body and helps to break down clots in the blood vessels.

However, The most common side effects of urokinase include bleeding, fever, headache, nausea, and vomiting. In rare cases, urokinase can cause more serious side effects, such as allergic reactions. Symptoms of an allergic reaction to urokinase may include urticaria (hives), difficulty breathing, swelling of the face or throat, chest pain, or a rapid or irregular heartbeat. These symptoms may require immediate medical attention. This restrains the market growth.

Moreover, there are some opportunities for the market such as Ongoing research activities for using urokinase in stroke patients. The ongoing research exploring the use of urokinase in stroke patients. Urokinase is a thrombolytic agent that can dissolve blood clots, and it has been used successfully in the treatment of other clot-related conditions such as pulmonary embolism and deep vein thrombosis.
  • The market is highly competitive, with many players involved in the development and marketing of urokinase products. Some of the key players in the market include Abbott Laboratories, Merck KGaA, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Ltd.

Market Segmentations

  • The Global Urokinase Market is segmented based on Type, Dose Strength, Indication, Applications, and Geography.
  • By Type, the market is classified into High Molecular Weight Urokinase and Low Molecular Weight Urokinase. High molecular weight urokinase has a larger molecular weight than low molecular weight urokinase and is typically used for the treatment of arterial thrombosis. Low molecular weight urokinase has a lower molecular weight and is used for the treatment of venous thrombosis.
  • By Dose Strength, the market is classified into 250,000 IU, 500,000 IU, and 750,000 IU. The 500,000 IU hold the largest market share. It is because the 500,000 IU dose strength are more commonly used because it provides an effective balance between potency and safety.
  • By Indication, the market is classified into Deep Vein Thrombosis, Pulmonary Embolism, and Myocardial Infarction. Deep Vein Thrombosis has the largest market share. This is due to the high prevalence of DVT and the effectiveness of urokinase in treating this condition.
  • By Applications, the market is classified into Hospitals & Clinics, Ambulatory Surgical Centers, and Others. The Hospitals & Clinics has the largest market share. It is due to the high demand for urokinase in these facilities. Hospitals and clinics are the primary settings where urokinase is used, as these facilities have the resources and staff to treat patients with serious medical conditions such as deep vein thrombosis, pulmonary embolism, and myocardial infarction.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific. The Americas region for the urokinase market is expected to be the largest due to the presence of well-established healthcare infrastructure and a high incidence of blood clotting disorders.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Abbott Laboratories, Merck KGaA, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Ltd., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Urokinase Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Urokinase Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Urokinase Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors.
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Rising Prevalence of Pulmonary Embolism Globally
4.2.2 Usage of Urokinase in the Treatment of Cardiovascular Disease
4.2.3 Growing Instances of Intracerebral Hemorrhage
4.3 Restraints
4.3.1 Urokinase is Contraindicated in Patients Suffering from Cancer and Brain Tumor
4.4 Opportunities
4.4.1 Ongoing Research Activities for Using Urokinase in Stroke Patients
4.4.2 Economic Development and Substantial Infrastructure Development
4.5 Challenges
4.5.1 Side Effects Such as Urticaria, Difficulty in Breathing, and Swelling of the Face
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 SWOT Analysis
5.5 Impact of COVID-19
5.6 Ansoff Matrix Analysis
6 Global Urokinase Market, By Type
6.1 Introduction
6.2 High Molecular Weight
6.3 Low Molecular Weight
7 Global Urokinase Market, By Dose Strength
7.1 Introduction
7.2 250,000 IU
7.3 500,000 IU
7.4 750,000 IU
8 Global Urokinase Market, By Indication
8.1 Introduction
8.2 Deep Vein Thrombosis
8.3 Pulmonary Embolism
8.4 Myocardial Infarction
9 Global Urokinase Market, By Applications
9.1 Introduction
9.2 Hospitals & Clinics
9.3 Ambulatory Surgical Centers
9.4 Others (Research Institutions, Pharmaceutical Companies, & CRO)
10 Americas' Urokinase Market
10.1 Introduction
10.2 Argentina
10.3 Brazil
10.4 Canada
10.5 Chile
10.6 Colombia
10.7 Mexico
10.8 Peru
10.9 United States
10.10 Rest of Americas
11 Europe's Urokinase Market
11.1 Introduction
11.2 Austria
11.3 Belgium
11.4 Denmark
11.5 Finland
11.6 France
11.7 Germany
11.8 Ireland
11.9 Italy
11.10 Luxembourg
11.11 Netherlands
11.12 Norway
11.13 Poland
11.14 Russia
11.15 Spain
11.16 Sweden
11.17 Switzerland
11.18 United Kingdom
11.19 Rest of Europe
12 Middle East and Africa's Urokinase Market
12.1 Introduction
12.2 Egypt
12.3 Israel
12.4 Nigeria
12.5 Qatar
12.6 Saudi Arabia
12.7 South Africa
12.8 United Arab Emirates
12.9 Rest of MEA
13 APAC's Urokinase Market
13.1 Introduction
13.2 Australia
13.3 Bangladesh
13.4 China
13.5 India
13.6 Indonesia
13.7 Japan
13.8 Malaysia
13.9 Philippines
13.10 Singapore
13.11 South Korea
13.12 Sri Lanka
13.13 Thailand
13.14 Taiwan
13.15 Rest of Asia-Pacific
14 Competitive Landscape
14.1 Competitive Quadrant
14.2 Market Share Analysis
15 Company Profiles
15.1 Abbott Laboratories
15.1.1 Company Overview
15.1.2 Company Snapshot
15.1.3 Product Overview
15.1.4 Business Overview
15.1.5 SWOT Analysis
15.1.6 Recent Developments
15.2 Boehringer Ingelheim International GmbH
15.2.1 Company Overview
15.2.2 Company Snapshot
15.2.3 Product Overview
15.2.4 Business Overview
15.2.5 SWOT Analysis
15.2.6 Recent Developments
15.3 Bristol-Myers Squibb Co.
15.3.1 Company Overview
15.3.2 Company Snapshot
15.3.3 Product Overview
15.3.4 Business Overview
15.3.5 SWOT Analysis
15.3.6 Recent Developments
15.4 Genentech, Inc.
15.4.1 Company Overview
15.4.2 Company Snapshot
15.4.3 Product Overview
15.4.4 Business Overview
15.4.5 SWOT Analysis
15.4.6 Recent Developments
15.5 Hainan Poly Pharm Co., Ltd.
15.5.1 Company Overview
15.5.2 Company Snapshot
15.5.3 Product Overview
15.5.4 Business Overview
15.5.5 SWOT Analysis
15.5.6 Recent Developments
15.6 Hualan Biological Engineering, Inc.
15.6.1 Company Overview
15.6.2 Company Snapshot
15.6.3 Product Overview
15.6.4 Business Overview
15.6.5 SWOT Analysis
15.6.6 Recent Developments
15.7 JCR Pharmaceuticals Co., Ltd.
15.7.1 Company Overview
15.7.2 Company Snapshot
15.7.3 Product Overview
15.7.4 Business Overview
15.7.5 SWOT Analysis
15.7.6 Recent Developments
15.8 Jiangsu Aidea Pharmaceutical Co., Ltd.
15.8.1 Company Overview
15.8.2 Company Snapshot
15.8.3 Product Overview
15.8.4 Business Overview
15.8.5 SWOT Analysis
15.8.6 Recent Developments
15.9 Livzon Pharmaceutical Group, Inc.
15.9.1 Company Overview
15.9.2 Company Snapshot
15.9.3 Product Overview
15.9.4 Business Overview
15.9.5 SWOT Analysis
15.9.6 Recent Developments
15.10 Merck KGaA
15.10.1 Company Overview
15.10.2 Company Snapshot
15.10.3 Product Overview
15.10.4 Business Overview
15.10.5 SWOT Analysis
15.10.6 Recent Developments
15.11 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
15.11.1 Company Overview
15.11.2 Company Snapshot
15.11.3 Product Overview
15.11.4 Business Overview
15.11.5 SWOT Analysis
15.11.6 Recent Developments
15.12 Novartis International Ag
15.12.1 Company Overview
15.12.2 Company Snapshot
15.12.3 Product Overview
15.12.4 Business Overview
15.12.5 SWOT Analysis
15.12.6 Recent Developments
15.13 Pfizer, Inc.
15.13.1 Company Overview
15.13.2 Company Snapshot
15.13.3 Product Overview
15.13.4 Business Overview
15.13.5 SWOT Analysis
15.13.6 Recent Developments
15.14 Sanofi SA
15.14.1 Company Overview
15.14.2 Company Snapshot
15.14.3 Product Overview
15.14.4 Business Overview
15.14.5 SWOT Analysis
15.14.6 Recent Developments
15.15 Shandong Qidu Pharmaceutical Co., Ltd.
15.15.1 Company Overview
15.15.2 Company Snapshot
15.15.3 Product Overview
15.15.4 Business Overview
15.15.5 SWOT Analysis
15.15.6 Recent Developments
15.16 Shanghai RAAS Blood Products Co., Ltd.
15.16.1 Company Overview
15.16.2 Company Snapshot
15.16.3 Product Overview
15.16.4 Business Overview
15.16.5 SWOT Analysis
15.16.6 Recent Developments
15.17 Sino Biological, Inc.
15.17.1 Company Overview
15.17.2 Company Snapshot
15.17.3 Product Overview
15.17.4 Business Overview
15.17.5 SWOT Analysis
15.17.6 Recent Developments
15.18 Teva Pharmaceutical Industries Ltd.
15.18.1 Company Overview
15.18.2 Company Snapshot
15.18.3 Product Overview
15.18.4 Business Overview
15.18.5 SWOT Analysis
15.18.6 Recent Developments
15.19 Wuhan Humanwell Healthcare Group Co., Ltd.
15.19.1 Company Overview
15.19.2 Company Snapshot
15.19.3 Product Overview
15.19.4 Business Overview
15.19.5 SWOT Analysis
15.19.6 Recent Developments
15.20 Zydus Cadila Healthcare Ltd.
15.20.1 Company Overview
15.20.2 Company Snapshot
15.20.3 Product Overview
15.20.4 Business Overview
15.20.5 SWOT Analysis
15.20.6 Recent Developments
16 Appendix
16.1 Self-Assessment Form

Companies Mentioned

  • Abbott Laboratories
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Genentech, Inc.
  • Hainan Poly Pharm Co., Ltd.
  • Hualan Biological Engineering, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Jiangsu Aidea Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group, Inc.
  • Merck KGaA
  • Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
  • Novartis International Ag
  • Pfizer, Inc.
  • Sanofi SA
  • Shandong Qidu Pharmaceutical Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Sino Biological, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Wuhan Humanwell Healthcare Group Co., Ltd.
  • Zydus Cadila Healthcare Ltd.

Table Information